Drugs With Tirzepatide Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
This Zepbound and Mounjaro Eye Side Effect NAION Information Page provides some important evidence regarding an increased risk of non-arteritic ischemic optic neuropathy, or NAION, associated with these two tirzepatide-containing drugs.
The FDA has been investigating “potential signals” of the eye side effect NAION with Mounjaro and Zepbound — the active ingredient is tirzepatide for both medications — as well as other glucagon-like peptide-1 (GLP-1) receptor agonist drugs, collectively referred to as GLP-1 RAs. To learn more about how Zepbound and Mounjaro might be associated with the eye side effect NAION, you can read our June 2025 Drug Injury Watch blog post, “Current FDA Safety Investigation: NAION With Mounjaro, Zepbound, and Other GLP-1 RAs”.
An August 2025 JAMA Network Open article, “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes“, provided more evidence for an increased risk of non-arteritic ischemic optic neuropathy, or NAION, with Ozempic (semaglutide) or Mounjaro (tirzepatide) in diabetes patients.
Here are some of the facts presented in that August 2025 medical article regarding the Mounjaro eye side effect NAION, specifically in diabetes patients:
- Nonarteritic anterior ischemic optic neuropathy (NAION) is characterized by loss of vision due to decreased blood flow to the optic nerve.
- The medical researchers compared Mounjaro (tirzepatide) with other antidiabetic medications for the associated risk of NAION in patients with type 2 diabetes who had no prior diagnosis of any eye disorder.
- Mounjaro (tirzepatide) is a newer and more potent GLP-RA to treat type 2 diabetes and obesity.
- In a population of patients with type 2 diabetes who had no prior diagnosis of eye diseases, this cohort study found that when Mounjaro (tirzepatide) was compared with other antidiabetic medications, there was an increased risk of NAION.
Besides Mounjaro, as we stated earlier, there is a second GLP-1RA drug that contains the active ingredient tirzepatide, Zepbound. That medication is used for obesity and weight loss purposes. There is some evidence that the NAION eye side effect may be associated with Zepbound, given that both drugs have the active ingredient tirzepatide.
Of course, we will continue to monitor relevant medical journals for additional studies concerning the association of NAION with Mounjaro and Zepbound. Further, we await the outcome of that FDA investigation into the eye side effect NAION with Mounjaro and Zepbound.
Free Case Evaluation for Zepbound or Mounjaro Eye Side Effect NAION
We encourage you to submit a Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Zepbound or Mounjaro drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Most Recent Articles About Zepbound and Mounjaro Eye Side Effect NAION With Vision Loss
Mounjaro and Ozempic NAION Vision Loss Lawsuits: Federal Court MDL No. 3163
As seen elsewhere on this Drug Injury Law website, we have been investigating Mounjaro and Ozempic NAION vision loss lawsuits seeking legal compensation for the person suffering from this serious eye side effect injury:
- Zepbound and Mounjaro Eye Side Effect NAION Information Page
- Eye-related Side Effects of Ozempic, Wegovy, and Rybelsus With Vision Loss
As indicated on those two webpages, Mounjaro NAION vision loss lawsuits would be filed against Eli Lilly, and Ozempic NAION vision loss lawsuits would be filed against Novo Nordisk.
To read more of this article, click below:
Because there are no warnings about NAION vision loss for Ozempic or Mounjaro in their current drug labels, those drug injury cases would only be filed against these responsible pharmaceutical companies — and not against patients’ doctors.
As regards the Mounjaro and Ozempic NAION vision loss lawsuits that are filed in federal courts, the U.S. Judicial Panel on Multidistrict Litigation (JPML) issued a December 2025 ruling that keeps these NAION lawsuits separate and apart from hundreds of earlier-filed Mounjaro and Ozempic cases involving gastrointestinal side effects.
The new federal court MDL case for the consolidation of Mounjaro and Ozempic NAION vision loss lawsuits is IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy [NAION] Products Liability Litigation, MDL No. 3163.
In addition to Mounjaro and Ozempic, this relatively new MDL No. 3163 lawsuits “consolidation” — which is not the same as a “class action”, but often confused with such — includes NAION cases involving a few other injectable GLP-1 agonist medicines from Eli Lilly (Zepbound) and Novo Nordisk (Wegovy and Rybelsus).
For these NAION vision loss lawsuits, we offer an online case evaluation service that is free and confidential, and without obligation:
Zepbound / Mounjaro Eye Side Effect NAION Case Evaluation Form
Ozempic / Wegovy / Rybelsus Vision Loss Case Evaluation Form
Experienced drug injury lawyer Tom Lamb will review your Case Evaluation Form, and he usually responds to you no later than the next business day.
If you would rather speak with Tom Lamb about your possible NAION eye side effect drug injury lawsuit, call him at 910-256-2971.
We look forward to assisting you or someone you know with a NAION case seeking legal compensation from the pharmaceutical drug company Eli Lilly (Mounjaro and Zepbound) or Novo Nordisk (Ozempic, Wegovy, and Rybelsus).
[Read the article in full at Drug Injury Watch]Earlier articles about eye-related side effects of Mounjaro and Zepbound:
- Ozempic and Mounjaro Increased Risk of NAION More Than Other Diabetes Drugs
- NAION With Tirzepatide-containing Drugs Mounjaro and Zepbound